Clinical Trial

Study for Participants With Relapsed/Refractory Non-Hodgkin Lymphoma

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
Open Label, Phase 1 study of CD19 t-haNK as a single agent and combination with rituximab in subjects with selected CD19+ and CD20+ R/R B-cell non-Hodgkin Lymphoma( NHL).
Protocol Amendment History 6 changes
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-07-11
notable Enrollment increased: 10 -> 20 participants 2026-07-11
notable Primary completion moved earlier: 2028-03 -> 2027-10 2026-07-11
minor Completion moved earlier: 2028-03 -> 2027-10 2026-07-11
notable Primary completion pushed: 2026-03-30 -> 2028-03 2026-05-05
minor Completion pushed: 2027-03-30 -> 2028-03 2026-05-05
Trial Details
NCT Number NCT06334991
Lead Sponsor ImmunityBio, Inc.
Conditions Non-Hodgkin Lymphoma Refractory/ Relapsed
Enrollment 20 participants
Start Date 2024-08-23
Primary Completion 2027-10 (estimated)
Study Completion 2027-10 (estimated)
Updated on ClinicalTrials.gov 2026-07-10